Interventional Glaucoma

The IOPtiMate laser-based system, from the Bio-Light Group, used for the non-invasive filtration treatment of glaucoma has received European Patent Office approval.

Ellex Medical Lasers Ltd. unveiled the latest version of its diagnostic ultrasound system (Eye Cubed) at the recent annual meeting of the American Academy of Ophthalmology.

Adrienne Graves, CEO of Santen Inc., has been appointed to the Glaucoma Research Foundation?s board of directors.

Hyperaemia is one of the main reasons why patients with glaucoma do not comply with or persist with their topical therapeutic regimen.

Participants in a survey showed low awareness that this option was available for patients with glaucoma.

A review of more than 20,000 glaucoma patients in Germany has discovered that 52.6% have a concomitant diagnosis of dry eye with women more likely to have both diseases than men.

Dr Randolph Evans argues that endocyclophotocoagulation (ECP) is a simple, safe and effective procedure for achieving IOP lowering in patients with medically controlled glaucoma who also require cataract surgery

The pathology of glaucoma is likely to be related to the presence and levels of selenium, according to the results of a study published in the August issue of the British Journal of Ophthalmology.

Application of genetic knowledge holds huge potential for the future and some believe that it has potential to become larger than the pharmaceutical market. Here Dr Alward examines what it has offered for the understanding and future treatment of glaucoma. Until recently, breakthroughs in glaucoma genetics emerged from painstaking family research, with the discovery of LOXL1 being the exception.

A question and answer session with a canaloplasty expert.

NicOx S.A. has signed an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open angle glaucoma and ocular hypertension. As part of this agreement, Pfizer has granted NicOx the right to access and use certain proprietary Xalatan (latanoprost) data.

OcumatRx, an early stage company that is developing a medical device that represents a new concept for the permanent treatment of patients with glaucoma, has announced the successful completion of clinical trials for their first device with favourable preliminary safety and tolerability.

Alcon Inc. announced it has discontinued development of anecortave acetate for the reduction of IOP associated with glaucoma.

Ronald Pitts Crick, the ophthalmologist who was behind the development of the operating microscope, has died aged 92.

A study by Italian researchers, the results of which have been published online by Eye, has found that both excimer laser trabeculotomy (ELT) and selective laser trabeculoplasty (SLT) are both equally effective treatment options for primary open angle glaucoma.

Ocular Therapeutics has signed non-disclosure agreements with two of the largest pharmaceutical firms in the world. The unnamed companies are interested in a new treatment approach in the largest of the ophthalmic markets.

Alcon has discontinued development of anecortave acetate for the reduction of intraocular pressure (IOP) associated with glaucoma.

A study reported in the July issue of Ophthalmology, the journal of the American Academy of Ophthalmology correlates the incidence of silent cerebral infarcts (SCI) and visual field loss in patients with normal-tension glaucoma.

Long-term SLT experience

Ocular applications of gene therapies are increasing, as is our understanding of the molecular pathogenesis of glaucoma.

The International Glaucoma Association (IGA) is urging people not to cut back on eye tests due to the recession.

Examing endoscopic cyclophotocoagulation as a treatment for ultra-refractory glaucoma patients.

Some of SLT's leading proponents share their short- and long-term findings with us and discuss the future potential of this treatment.

Looking at OCT as a sensitive diagnostic test for glaucomatous progression.

During the recent ARVO congress, Sylentis provided an update on recent advances made by the company in the development a product for ocular pain associated with dry eye syndrome that addresses TRPV1 receptor, a nociceptor able to transmit stimuli.